MUC2 and prostate cancer: We observed the MUC2 T1750N variant in breast cancer [DOID:1612], liver cancer [DOID:3571], thyroid cancer [DOID:1781], ovarian cancer [DOID:2394], prostate cancer [DOID:10283], brain cancer [DOID:1319], and rectum cancer [DOID:1993].